Table 2.
Therapeutic protocols of the patients included in the study.
| BCRL+ (n = 75) | BCRL− (n = 293) | p-Value | |
|---|---|---|---|
| Breast surgery, n (%) | |||
| Conservative | 47 (62.7) | 177 (60.4) | 0.7208 |
| Mastectomy | 28 (37.3) | 116 (39.6) | |
| Axillary surgery, n (%) | |||
| En bloc dissection | 75 (100.0) | 274 (93.5) | 0.0178 |
| Sentinel lymph node | 0 (0.0) | 19 (6.5) | |
| Radiotherapy, n (%) | |||
| No WBI WBI + SCF SCF + CW |
21 (28.0) 36 (48.0) 7 (9.3) 11 (14.7) |
78 (26.6) 153 (52.2) 16 (5.5) 46 (15.7) |
0.6318 |
| Chemotherapy, n (%) | |||
| No Taxanes Other protocols |
22 (29.3) 45 (60.0) 8 (10.7) |
153 (52.2) 110 (37.5) 30 (10.2) |
0.0010 |
| Hormone therapy, n (%) | |||
| No SERM Aromatase inhibitors SERM + Aromatase inhibitors SERM + LHRH agonists |
14 (18.7) 6 (8.0) 34 (45.3) 11 (14.7) 10 (13.3) |
36 (12.3) 43 (14.7) 135 (46.1) 44 (15.0) 35 (12.0) |
0.4206 |
| Duration of the intake (days), median (Q1, Q3) | |||
| SERM Aromatase inhibitors LHRH agonists |
301 (252; 349) 1586 (1095; 1827) 1200 (731; 1358) |
300 (216; 371) 1544 (967; 1836) 989 (708; 1765) |
1.0000 0.8658 0.9343 |
| Trastuzumab, n (%) | 11 (14.7) | 19 (6.5) | 0.0209 |
| Breast surgery, n (%) | |||
| Conservative | 47 (62.7) | 177 (60.4) | 0.7208 |
| Mastectomy | 28 (37.3) | 116 (39.6) | |
| Axillary surgery, n (%) | |||
| En bloc dissection | 75 (100.0) | 274 (93.5) | 0.0178 |
| Sentinel lymph node | 0 (0.0) | 19 (6.5) | |
| Radiotherapy, n (%) | |||
| No WBI WBI + SCF SCF + CW |
21 (28.0) 36 (48.0) 7 (9.3) 11 (14.7) |
78 (26.6) 153 (52.2) 16 (5.5) 46 (15.7) |
0.6318 |
| Chemotherapy, n (%) | |||
| No Taxanes Other protocols |
22 (29.3) 45 (60.0) 8 (10.7) |
153 (52.2) 110 (37.5) 30 (10.2) |
0.0010 |
| Hormone therapy, n (%) | |||
| No SERM Aromatase inhibitors SERM + Aromatase inhibitors SERM + LHRH agonists |
14 (18.7) 6 (8.0) 34 (45.3) 11 (14.7) 10 (13.3) |
36 (12.3) 43 (14.7) 135 (46.1) 44 (15.0) 35 (12.0) |
0.4206 |
| Duration of the intake (days), median (Q1, Q3) | |||
| SERM Aromatase inhibitors LHRH agonists |
301 (252; 349) 1586 (1095; 1827) 1200 (731; 1358) |
300 (216; 371) 1544 (967; 1836) 989 (708; 1765) |
1.0000 0.8658 0.9343 |
| Trastuzumab, n (%) | 11 (14.7) | 19 (6.5) | 0.0209 |
BCRL, breast cancer related lymphedema; WBI, whole breast irradiation; SCF, supraclavicular fossa; CW, chest wall; SERM, selective estrogen receptor modulator (Tamoxifen); LHRH, luteinizing hormone releasing hormone agonist; Q1, quartile 1; Q3, quartile 3.